There was a press release yesterday from Galapagos NV detailing a new clinical trial for one of their existing drug candidates. It came as no surprise that Charley’s Fund is helping to fund the trial, along with the Nash Avery Foundation. This is what Charley’s Fund focuses on. If money from donors is the fuel and research is the engine, Charley’s Fund is the filling station, pooling money from donors that is then used to drive these research engines with the ultimate goal of finding an effective therapy and cure for Duchenne Muscular Dystrophy.
Their drive and passion is truly inspirational. Their combination of grace and determination and tireless commitment to their cause has resulted in real progress towards the singular goal. It is an exciting time and there has been some incredible progress made, but there is more to do. We can all help. Please donate to Charley’s Fund or the Nash Avery Foundation. Buy the Live Inspired app. Purchase a Darius Goes West DVD. Our collective donations will fund research that will result in a therapy for DMD for this generation of boys. Below are some quotes from the press release. The full release is available here.
“Charley’s Fund and the Nash Avery Foundation will support the costs of pre-clinical studies to assess the potential effectiveness of G100192 in treating Duchenne muscular dystrophy.”
“The SARM therapeutic that Galapagos is developing for cachexia could be of potential benefit in treating Duchenne muscular dystrophy,” said Benjamin Seckler, M.D., President of Charley’s Fund. “If the pre-clinical models show efficacy in treating this disease, G100192 could become one of the first small molecule candidate drugs for Duchenne – complementing the gene therapy and biologic approaches in development.”